Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
October 29, 2019
Oncotarget

Neuroblastoma cells treated with RXDX-105, a small-molecule inhibitor of multiple kinases decreased cell viability and proliferation in vitro and in vivo.

CTD²
October 08, 2019
Blood Advances

Epigenomic analysis of methylation data using Onco-GPS computational approach identify subtypes of myelodysplastic syndromes. The subtypes had distinct patterns of genetic lesions, regulatory region methylation, and prognostic response.

CTD²
October 04, 2019
Protein-Protein Interaction Networks: Book Chapter
CTD²
September 25, 2019
Nature Communications

Metabolic profiling of serum samples indicated an increase in kynurenine in melanoma and renal cell carcinoma patients treated with immune-checkpoint inhibitor, nivolumab. An increase in kynurenine, a product of tryptophan catabolism, correlates with worse overall survival.

CTD²
September 19, 2019
Cell Chemical Biology

Scientists at the Broad Institute CTD2 Center identified 6-phosphogluconate dehydrogenase, a cytosolic enzyme as a link between carbohydrate metabolism and protein secretion.

CTD²
September 13, 2019
Expert Review of Proteomics

A review article on understanding ovarian cancer at the protein-level using large-scale proteomic technologies and proteomic studies.

CTD²
September 05, 2019
Cell Stem Cell

CTD2 scientists at UCSF showed that neuroepithelial stem cells derived from normal induced pluripotent stem cells could be a powerful experimental resource to evaluate genetic mutations in medulloblastoma.

CTD²
September 01, 2019
Nature

Scientists at Johns Hopkins University showed that E-cadherin is an essential factor in the seeding phases of metastasis in invasive ductal carcinomas. This is mediated by limiting reactive oxygen-mediated apoptosis.

CTD²
September 01, 2019
Cancer Research

CTD2 scientists show that metformin suppresses the expression of head and neck squamous cell carcinoma (HNSCC) stem cell programs, causes loss of expression of cancer stem cell markers, and promotes terminal differentiation. This study informs the selection of patients at risk of developing HNSCC.

Pages

CSVXML